P Frühling1, A Nilsson2, F Duraj3, U Haglund4, A Norén5. 1. Department of Surgical Sciences, Upper Abdominal Surgery, Uppsala University, Uppsala, Sweden. Electronic address: petter.fruhling@surgsci.uu.se. 2. Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden. Electronic address: anders.Nilsson@radiol.uu.se. 3. Department of Surgical Sciences, Upper Abdominal Surgery, Uppsala University, Uppsala, Sweden. Electronic address: frans.duraj@surgsci.uu.se. 4. Department of Surgical Sciences, Upper Abdominal Surgery, Uppsala University, Uppsala, Sweden. Electronic address: ulf.haglund@surgsci.uu.se. 5. Department of Surgical Sciences, Upper Abdominal Surgery, Uppsala University, Uppsala, Sweden. Electronic address: agneta.noren@surgsci.uu.se.
Abstract
INTRODUCTION: A single-center nonrandomized clinical trial was performed to assess the safety and efficacy of IRE ablation of liver tumors in humans. METHODS: 38 malignant liver tumors on 30 patients were treated with IRE between September 2011 and September 2014. Treatment was with curative intent, and the diagnoses were colorectal cancer with liver metastases (CRLM) (n = 23), hepatocellular carcinoma (HCC) (n = 8) and other metastasis (n = 7). Patients were selected when surgery, radiofrequency ablation (RFA) or microwave ablation (MWA) was not an option, and when they met inclusion criteria (tumor size < 3 cm, 1-2 tumors). Patients were followed-up at 1 and 6 months with a contrast-enhanced computed tomography (CE-CT), and contrast-enhanced ultrasound (CE-US) at 3 months. RESULTS: Ablation success was defined as no evidence of residual tumor in the ablated area as confirmed by CE-CT and CE-US. At 3 months ablation success was 78.9%, and 65.8% at 6 months. There was no statistically significant difference between tumor volume (<5 cm3 vs >5 cm3, p = 0.518), and between diagnosis (CRLM vs HCC, p = 0.084) in terms of local recurrence. Complications were classified according to the standardized grading system of Society of Interventional Radiology (SIR). A minor complication occurred in six patients (20%), one patient (3.3%) suffered from a major complication (bile duct dilatation and stricture of the portal vein and bile duct). No mortalities occurred at 30 days. CONCLUSIONS: IRE appears to be a safe treatment modality for a selected group of patients with liver tumors and offers high local tumor control at 3 and 6 months.
INTRODUCTION: A single-center nonrandomized clinical trial was performed to assess the safety and efficacy of IRE ablation of liver tumors in humans. METHODS: 38 malignant liver tumors on 30 patients were treated with IRE between September 2011 and September 2014. Treatment was with curative intent, and the diagnoses were colorectal cancer with liver metastases (CRLM) (n = 23), hepatocellular carcinoma (HCC) (n = 8) and other metastasis (n = 7). Patients were selected when surgery, radiofrequency ablation (RFA) or microwave ablation (MWA) was not an option, and when they met inclusion criteria (tumor size < 3 cm, 1-2 tumors). Patients were followed-up at 1 and 6 months with a contrast-enhanced computed tomography (CE-CT), and contrast-enhanced ultrasound (CE-US) at 3 months. RESULTS: Ablation success was defined as no evidence of residual tumor in the ablated area as confirmed by CE-CT and CE-US. At 3 months ablation success was 78.9%, and 65.8% at 6 months. There was no statistically significant difference between tumor volume (<5 cm3 vs >5 cm3, p = 0.518), and between diagnosis (CRLM vs HCC, p = 0.084) in terms of local recurrence. Complications were classified according to the standardized grading system of Society of Interventional Radiology (SIR). A minor complication occurred in six patients (20%), one patient (3.3%) suffered from a major complication (bile duct dilatation and stricture of the portal vein and bile duct). No mortalities occurred at 30 days. CONCLUSIONS: IRE appears to be a safe treatment modality for a selected group of patients with liver tumors and offers high local tumor control at 3 and 6 months.
Authors: Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami Journal: Diagnostics (Basel) Date: 2022-05-24
Authors: C Matthew Hawkins; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh S Thakor; Richard B Towbin; Anne Marie Cahill; Matthew P Lungren Journal: Pediatr Radiol Date: 2018-02-02
Authors: Chelsea M Edelblute; James Hornef; Niculina I Burcus; Thomas Norman; Stephen J Beebe; Karl Schoenbach; Richard Heller; Chunqi Jiang; Siqi Guo Journal: Sci Rep Date: 2017-09-18 Impact factor: 4.379
Authors: Chelsea M Edelblute; Siqi Guo; James Hornef; Enbo Yang; Chunqi Jiang; Karl Schoenbach; Richard Heller Journal: Technol Cancer Res Treat Date: 2018-01-01
Authors: Christopher Livia; Alan Sugrue; Tyra Witt; Murray D Polkinghorne; Elad Maor; Suraj Kapa; Helge I Lehmann; Christopher V DeSimone; Atta Behfar; Samuel J Asirvatham; Christopher J McLeod Journal: J Am Heart Assoc Date: 2018-08-07 Impact factor: 5.501